Download Files:

Ziprasidone (hydrochloride)

Products Details

Product Description

– Ziprasidone (CP-88059) hydrochloride is an orally active combined 5-HT and dopamine receptor antagonist[1]. Ziprasidone hydrochloride has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM)[1].

Web ID

– HY-14542A

Shipping

– Room temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C21H22Cl2N4OS

References

– [1]Rollema H, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48(3):229-237.|[2]Schmidt AW, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425(3):197-201.|[3]Seeger TF, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995;275(1):101-113.|[4]Park S, et al. The effect of ziprasidone on body weight and energy expenditure in female rats. Metabolism. 2012;61(6):787-793.

CAS Number

– 122883-93-6

Molecular Weight

– 449.40

SMILES

– ClC1=CC2=C(CC(N2)=O)C=C1CCN(CC3)CCN3C4=NSC5=C4C=CC=C5.Cl

Clinical Information

– Launched

Research Area

– Neurological Disease

Solubility

– 10 mM in DMSO

Target

– 5-HT Receptor;Dopamine Receptor

Isoform

– 5-HT1 Receptor;5-HT2 Receptor;D2 Receptor

Pathway

– GPCR/G Protein;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=